New pill targets Hard-to-Treat cancers: early trial recruits 554 patients

NCT ID NCT05786924

Recruiting now Disease control Sponsor: Institut de Recherches Internationales Servier Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or with other cancer drugs. About 554 adults with lung, colorectal, pancreatic, or other cancers will take the drug daily in 28-day cycles. The goal is to see if the drug can shrink tumors or slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: S241656 (also called BDTX-4933), an oral RAF inhibitor
What this could lead to: If successful, this could provide a new treatment option for people with advanced cancers that have specific genetic mutations (like KRAS or BRAF) and have not responded to other therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not work as hoped or could cause unexpected side effects. It is also testing many different cancer types and combinations, making it harder to prove benefit for any single group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACQUIRED RESISTANCE TO KRAS G12C INHIBITOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer brain cancer carcinoma colorectal cancer colorectal carcinoma colorectal neoplasm histiocytic and dendritic cell neoplasm histiocytic sarcoma histiocytosis lung cancer lung neoplasm metastatic malignant neoplasm metastatic malignant neoplasm in the brain neoplasm non-small cell lung carcinoma pancreatic ductal adenocarcinoma thyroid cancer thyroid gland carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACQUIRED RESISTANCE TO KRAS G12C INHIBITOR BRAF BRAF GENE MUTATION BRAF MUTATION-RELATED TUMORS BRAF V600 MUTATION BRAF V600E BRAIN METASTASES COLORECTAL CANCER COLORECTAL CARCINOMA HISTIOCYTIC NEOPLASM HISTIOCYTOSIS KRAS G12A KRAS G12D KRAS G12F KRAS G12R KRAS G12V KRAS G13C KRAS G13D KRAS MUTATION-RELATED TUMORS METASTATIC LUNG CANCER METASTATIC LUNG NON-SMALL CELL CARCINOMA NON-SMALL CELL LUNG CANCER NRAS GENE MUTATION NSCLC RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM RECURRENT LUNG CANCER RECURRENT LUNG NON-SMALL CELL CARCINOMA RECURRENT NSCLC SOLID CARCINOMA SOLID TUMOR THYROID CANCER THYROID CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Banner Health- MD Anderson Cancer Center
RECRUITING

Gilbert, Arizona, 85234, United States
Center for Cancer and Organ Diseases - Rigshospitalet
RECRUITING

Copenhagen, 2100, Denmark
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Duke University School of Medicine
RECRUITING

Durham, North Carolina, 27710, United States
Fred Hutchinson Cancer Research Center
RECRUITING

Seattle, Washington, 98109, United States
Georgetown University Lombardi Cancer Center
NOT_YET_RECRUITING

Washington D.C., District of Columbia, 20007, United States
Hammersmith Hospital
RECRUITING

London, W12 0HS, United Kingdom
Kyoto University Hospital
RECRUITING

Kyoto, 606-8507, Japan
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Masonic Cancer Center University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute)
RECRUITING

New York, New York, 10016, United States
National Cancer Center Hospital
RECRUITING

Tokyo, 104-0045, Japan
Queen Mary Hospital
RECRUITING

Hong Kong, Hong Kong
START San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
Sarah Canon Research Institute (SCRI) Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
South Texas Accelerated Research Therapeutics (START) Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
The Angeles clinic - A cedars SINAI AFFILIATE
RECRUITING

Los Angeles, California, 90025, United States
The Christie NHS Foundation Trust
RECRUITING

Manchester, M20 4BX, United Kingdom
USC Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90033, United States
University College London Hospital
RECRUITING

London, NW1 2PG, United Kingdom
University of California, San Francisco (UCSF)
RECRUITING

San Francisco, California, 94143, United States
University of Colorado - Aurora Cancer Center
NOT_YET_RECRUITING

Aurora, Colorado, 80045, United States
Washington University
RECRUITING

St Louis, Missouri, 63130, United States
Yale University School of Medicine - Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06520-8028, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.